Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Phillips JL et al. | 1986 | intact cell/cell culture, human colon carcinoma cell line (Colo 205 and Colo 320 DM) | electric field, magnetic field, 50/60 Hz | 100 µT |
Phillips JL | 1986 | intact cell/cell culture, human colon carcinoma cell line (Colo 205) | electric field, magnetic field, 50/60 Hz | 0.1 mT |
Goodman R et al. | 1994 | intact cell/cell culture, HL-60 cells (human acute myeloid leukaemia cell line) and yeast cells (<i>Saccharomyces cerevisiae</i>) | electric field, magnetic field, 50/60 Hz | 0.1–80 µT |
Greene JJ et al. | 1991 | intact cell/cell culture, HL-60 cells (human acute myeloid leukaemia cell line) | electric field, magnetic field, 50/60 Hz | 1 mT |
Lin H et al. | 1994 | intact cell/cell culture, HeLa cell line (human adenocarcinoma cell line), transfected | electric field, magnetic field, 50/60 Hz, shielding/field deprivation | 8–80 µT |
Antonini RA et al. | 2006 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | low frequency, 50/60 Hz, power transmission line, magnetic field | 1–2 mT |
Ning J et al. | 1992 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), Daudi (Burkitt's lymphoma cell line) cells and normal human lymphocytes | low frequency, signals/pulses, 50/60 Hz, magnetic field | 0.1 mT |
Karabakhtsian R et al. | 1994 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz | 8 µT |
Desjobert H et al. | 1995 | intact cell/cell culture, human Epstein-Barr-virus-immortalized lymphoid cells and human leukemic cell line (HL-60) | magnetic field, 50/60 Hz | 10 µT–1 mT |
Goodman R et al. | 1992 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz | 80 µT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.